Appeal No. 1997-2188
Application 08/137,440
of claim 30. Appellants direct our attention to the
specification at page 7, lines 6 through 8 wherein it is
disclosed that certain galanthamine derivatives cleave to form
in situ the compound 6-O-demethylgalanthamine which is
admitted by appellants to be a known AChE inhibitor.
Appellants urge that the claim, therefor, is directed to
administering the compounds of claim 4 to form, in situ, the
admittedly known AChE inhibitor 6-O-demethylgalantha-mine.
While we agree with the examiner's conclusion that claim
30 is not a model of clarity, we find the claim adequately
defines the metes and bounds of what appellants intend to
claim by the claim language. We find claim 30 to be directed
to administering an AChE inhibiting amount of the galanthamine
derivative of claim 4 which metabolizes in situ to form 6-O-
demethylgalanthamine. Accordingly, the rejection is reversed.
SUMMARY
The rejection of claims 1 through 30 under 35 U.S.C. §
112, first paragraph, is reversed. The rejection of claim 30
under 35 U.S.C. § 112, second paragraph, is reversed.
The decision of the examiner is reversed.
REVERSED.
19
Page: Previous 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 Next
Last modified: November 3, 2007